Flamel Technologies Announces Projected Release Date of Third Quarter 2012 Results and Conference Call
31 10월 2012 - 5:05AM
Marketwired
Flamel Technologies (NASDAQ: FLML) expects to release certain
financial results for the third quarter of 2012, on Monday,
November 5th, before the market open. A conference call to discuss
these results has been scheduled for Monday, November 5th, at 8:30
AM (Eastern Standard Time). A question and answer period will
follow management's prepared remarks.
To participate in the conference call, investors are invited to
dial 888-438-5524. The conference ID number is 9243089. The
conference call webcast may be accessed at www.flamel.com.
A replay of the call will be available for 14 days, within a few
hours after the call ends. Investors may listen to the replay of
the call by dialing 888-203-1112 (U.S.) or +1-719-457-0820
(international), with the passcode 9243089. A replay of the webcast
will also be archived on Flamel's website for 90 days following the
call.
About Flamel Technologies. Flamel
Technologies SA's (NASDAQ: FLML) business model is to blend
high-value internally developed products with its leading drug
delivery capabilities. The Company has a proprietary pipeline of
niche specialty pharmaceutical products, while its drug delivery
platforms are focused on the goal of developing safer, more
efficacious formulations of drugs to address unmet medical needs.
Its partnered pipeline includes biological and chemical drugs
formulated with the Medusa® and Micropump® proprietary drug
delivery platforms. Several Medusa-based products are currently in
the clinical stages of development; Medusa's lead internal product
candidate IFN-alpha XL (long-acting interferon alpha-2b) is being
evaluated in a Phase 2b trial in HCV patients. The Company has
developed products and manufactures Micropump-based microparticles
under FDA-audited GMP guidelines. Flamel has collaborations with a
number of leading pharmaceutical and biotechnology companies,
including GlaxoSmithKline (Coreg CR®, carvedilol phosphate) and
Merck Serono (long acting interferon beta 1a). Flamel is
headquartered in Lyon, France and has operations in St. Louis,
Missouri, and manufacturing facilities in Pessac, France.
Additional information may be found at www.flamel.com.
This release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995,
including certain plans, expectations, goals and projections
regarding financial results, product developments and technology
platforms. All statements that are not clearly historical in nature
are forward-looking, and the words "anticipate," "assume,"
"believe," "expect," "estimate," "plan," "will," "may," and similar
expressions are generally intended to identify forward-looking
statements. All forward-looking statements involve risks,
uncertainties and contingencies, many of which are beyond our
control that could cause actual results to differ materially from
those contemplated in such forward-looking statements. These risks
include risks that the acquisition of Éclat Pharmaceuticals may not
be successfully integrated or that certain payment acceleration
events may be triggered; the expected timing of the filing of our
first New Drug Application (NDA) with the FDA may be delayed; the
identified opportunities will not result in shorter-term, high
value results; clinical trial results may not be positive or our
partners may decide not to move forward; management transition to a
new chief executive officer may be disruptive or not succeed as
planned; products in the development stage may not achieve
scientific objectives or milestones or meet stringent regulatory
requirements; products in development may not achieve market
acceptance; competitive products and pricing may hinder our
commercial opportunities; we may not be successful in identifying
and pursuing opportunities to develop our own product portfolio
using Flamel's technology; and the risks associated with our
reliance on outside parties and key strategic alliances. These and
other risks are described more fully in Flamel's Annual Report on
Form 20-F for the year ended December 31, 2011 that has been filed
with the Securities and Exchange Commission (SEC). All
forward-looking statements included in this release are based on
information available at the time of the release. We undertake no
obligation to update or alter our forward-looking statements as a
result of new information, future events or otherwise.
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024